Screener
CONMED CNMD D&A
D&A at other companies
Other financials
Where this comes from
Reported directly by CONMED in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: CONMED’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000816956-26-000102
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income | $36,899 | $27,457 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation | 8,253 | 8,701 |
| Amortization of deferred debt issuance costs | 2,330 | 2,831 |
| Amortization | 29,630 | 28,123 |
| Stock-based compensation | 10,732 | 18,766 |
| Deferred income taxes | 3,683 | (975) |
Item 1. Financial Statements (unaudited)
FAQ
- What is CONMED's D&A?
- CONMED (CNMD) reported D&A of $4.08M in Q2 2026.
- How has CONMED's D&A changed year-over-year?
- CONMED's D&A decreased by 8.7% year-over-year, from $4.47M to $4.08M.
- What is the long-term trend for CONMED's D&A?
- Over 4 years (2021 to 2025), CONMED's D&A has grown at a 1.0% compound annual growth rate (CAGR), from $16.49M to $17.14M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about CONMED's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude